0      0

28th Annual North American Cystic Fibrosis Conference


S11: INF/MIC: Multiple Inhaled Antibiotics: Multiple Therapeutic Considerations


Oct 10, 2014 10:30am ‐ Oct 10, 2014 12:20pm

Standard: $49.99

Description

Suppressive antibiotic treatment of CF patients with chronic P. aeruginosa airway infection is the standard of care in Europe and North America. With the recent inhaled aztreonam approval, there are now three antipseudomonal antibiotic classes that are readily available and commonly utilized to manage chronic P. aeruginosa airway infections: polymyxins (colistimethate), aminoglycosides (gentamicin, tobramycin) and beta lactams (aztreonam). These agents have all been studied and developed as monotherapies, but there is growing interest in the use of these agents in various combinations in individual patients to improve outcomes and extend the period of efficacy of suppressive treatment.

Learning Objectives:
  • Review how treatment patterns among patients among US CF patients have changed with the introduction of a third class of inhaled antipseudomonal antibiotic
  • Discuss the ramifications of multiple inhaled antibiotic use with respect to design and execution future inhaled antibiotic studies of either newer members of existing antibiotic classes or new antibiotic classes
  • Examine how the results of large clinical studies conducted to date have informed our understanding (or lack thereof) of the mechanism(s) of inhaled antibiotic efficacy

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content